EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis

Documenti analoghi

• CD74–ROS1 L2026M mutant enhances autophagy through the MEK / ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells
  di: Xiaobo Xu, et al.
  Pubblicazione: (2024)
• SMARCB1‐deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman
  di: Megumi Nobuoka, et al.
  Pubblicazione: (2024)
• A case of inflammatory myofibroblastic tumor harboring EML4‐ALK fusion with a brain metastasis responding to alectinib
  di: Soichiro Sakoda, et al.
  Pubblicazione: (2024)
• Lung Adenocarcinoma Expressing an EML4‐ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report
  di: Mami Ozaki, et al.
  Pubblicazione: (2025)
• Population modeling analyses of crizotinib in pediatric patients with ALK‐positive advanced cancers
  di: Li Jerry, et al.
  Pubblicazione: (2024)